A teenager has been suffering from atopic dermatitis for years after it appeared during his elementary school years. He could barely sleep at night because of the severe itchiness, which made him scratch his skin all night, leaving him bleeding.
JW1601, an oral atopy treatment candidate that was licensed by JW Pharmaceutical to Ballerup, Denmark-based Leo Pharma began Phase 2 clinical trials, the Korean company said Wednesday.
Korea JoongAng Daily Sitemap
